Just for shits and giggles let’s look assume their intention has always been to sell the company for the most bucks possible.
It appeared they delayed the submission for the second indication. Perhaps they did this to give the drug time to be on the market around one year before the second indication is approved. I’m sure they expect to drug to capture decent market share, prove itself more user friendly, and have much better tolerability than the competition in the real world setting by early next year when they get the second approval. That might be the ideal time to cash in their chips... Genius
News 
Market Data 
Discover 
